Literature DB >> 30965233

The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases.

Jiamei Chen1, Yonghong Hu1, Long Chen1, Wei Liu1, Yongping Mu1, Ping Liu2.   

Abstract

Fuzheng Huayu formula (FZHY) is a traditional Chinese medicine formula composed of Radix Salvia Miltiorrhizae, Cordyceps, Semen Persicae, Gynostemma Pentaphyllammak, Pollen Pini, Fructus Schisandrae Chinensis that is used to treat chronic liver diseases in China. We here describe the pharmacological actions of FZHY in this review. We also describe and provide updates on recent advances in the medical applications and the basic research of mechanisms of FZHY formula. FZHY has been shown to have no serious adverse reactions and exerts antifibrotic effects through targeting more than one molecule.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Antifibrotic effect; Chronic liver disease; Clinical application; Fuzheng Huayu; Mechanism

Mesh：

Substances：

Year:  2019        PMID： 30965233     DOI： 10.1016/j.biopha.2019.108846

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


  9 in total

Review 1.  Panax ginseng C. A. Meyer as a potential therapeutic agent for organ fibrosis disease.

Authors:  Hao Liu; Chongning Lv; Jincai Lu
Journal:  Chin Med       Date:  2020-11-24       Impact factor: 5.455

2.  An Herbal Product Alleviates Bleomycin-Induced Pulmonary Fibrosis in Mice via Regulating NF-κB/TNF-α Signaling in Macrophages.

Authors:  Fei Jing; Xi Chen; Jingbo Xue; Kai Huang; Feng Xing; Xudong Hu; Yuan Peng; Chenghai Liu
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.988

3.  Simultaneous determination of eight analytes of Fuzheng Huayu recipe in beagle dog plasma by UHPLC-Q/exactive Orbitrap HRMS and its application to toxicokinetics.

Authors:  Yu-Lin Wang; Ming-Jv Yang; Rong-Sheng Li; Ye-Qing Hu; Yi-Feng Pan; Tao Yang
Journal:  Biomed Chromatogr       Date:  2022-01-22       Impact factor: 1.911

4.  Cardiovascular disease due to novel coronavirus and the search for investigational therapies.

Authors:  Albeir Y Mousa; Mike Broce; B Daniel Lucas
Journal:  J Vasc Surg       Date:  2020-05-17       Impact factor: 4.268

5.  Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.

Authors:  Dong Ji; Yan Chen; Qinghua Shang; Huabao Liu; Lin Tan; Jing Wang; Yongping Chen; Qin Li; Qinghua Long; Laicheng Song; Li Jiang; Guangming Xiao; Zujiang Yu; Liang Chen; Xiaoyu Hu; Xiaodong Wang; Da Chen; Zhiqin Li; Zheng Dong; Guofeng Chen; Yongping Yang
Journal:  Am J Gastroenterol       Date:  2021-04-08       Impact factor: 10.864

Review 6.  Potential Therapeutic Strategies for Renal Fibrosis: Cordyceps and Related Products.

Authors:  Wei Tan; Yunyan Wang; Hongmei Dai; Junhui Deng; Zhifen Wu; Lirong Lin; Jurong Yang
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

Review 7.  Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products Against COVID-19: Update on Clinical Trials and Mechanism of Actions.

Authors:  Safaet Alam; Md Moklesur Rahman Sarker; Sadia Afrin; Fahmida Tasnim Richi; Chao Zhao; Jin-Rong Zhou; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

Review 8.  Role of gut microbiota in identification of novel TCM-derived active metabolites.

Authors:  Tzu-Lung Lin; Chia-Chen Lu; Wei-Fan Lai; Ting-Shu Wu; Jang-Jih Lu; Young-Mao Chen; Chi-Meng Tzeng; Hong-Tao Liu; Hong Wei; Hsin-Chih Lai
Journal:  Protein Cell       Date:  2020-09-15       Impact factor: 14.870

9.  Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis.

Authors:  Ke Shi; Yao Liu; Xiaojing Wang; Yuxin Li; Qun Zhang; Ying Hu; Chongping Ran; Yunyi Huang; Jie Hou; Xianbo Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-29       Impact factor: 2.629
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.